Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Nov 14, 2017 • 5:25 PM EST
Ligand Provides Highlights from Today’s Analyst Day Event
Nov 9, 2017 • 4:01 PM EST
Ligand Reports Third Quarter 2017 Financial Results
Nov 6, 2017 • 9:00 AM EST
Reminder: Ligand to Host Analyst Day on November 14th in New York City
Nov 14, 2017 • 4:00pm EST
New York, NY
See all events
Nov 7, 2017 • 1:00pm EST
Sep 11, 2017 • 1:45pm EST
Lotte New York Palace Hotel, New York, NY
$SPPI highlights EVOMELA abstracts for upcoming #ASH17 59th annual meeting https://t.co/XBGpNzLMOR
$ALDX presents noninfectious anterior uveitis Phase 2 data for Reproxalap to the American Uveitis Society held at t… https://t.co/FkBTHES8eD
$VKTX announces positive top-line results from Phase 2 study of VK5211 in patients recovering from hip fracture https://t.co/rvisnCBNEg